- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Patent holdings for IPC class A61K 31/437
Total number of patents in this class: 10354
10-year publication summary
581
|
583
|
647
|
645
|
622
|
613
|
652
|
597
|
699
|
572
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 4850 |
182 |
F. Hoffmann-La Roche AG | 7947 |
136 |
Incyte Corporation | 1028 |
135 |
Genentech, Inc. | 4012 |
122 |
Takeda Pharmaceutical Company Limited | 2706 |
122 |
Novartis AG | 10709 |
113 |
Janssen Pharmaceutica N.V. | 3370 |
105 |
Merck Sharp & Dohme LLC | 3756 |
100 |
Boehringer Ingelheim International GmbH | 4648 |
98 |
Gilead Sciences, Inc. | 2060 |
91 |
Merck Patent GmbH | 5773 |
85 |
The Regents of the University of California | 20137 |
70 |
Bayer Pharma AG | 1054 |
69 |
Hoffmann-La Roche Inc. | 3484 |
68 |
Abbvie Inc. | 1802 |
68 |
Dana-Farber Cancer Institute, Inc. | 2600 |
65 |
Pfizer Inc. | 3391 |
63 |
Plexxikon Inc. | 148 |
59 |
Galapagos NV | 274 |
57 |
Taisho Pharmaceutical Co., Ltd. | 865 |
56 |
Other owners | 8490 |